JP2013100314A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013100314A5 JP2013100314A5 JP2013000244A JP2013000244A JP2013100314A5 JP 2013100314 A5 JP2013100314 A5 JP 2013100314A5 JP 2013000244 A JP2013000244 A JP 2013000244A JP 2013000244 A JP2013000244 A JP 2013000244A JP 2013100314 A5 JP2013100314 A5 JP 2013100314A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- drug conjugate
- composition
- conjugate according
- psma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims description 29
- 239000012634 fragment Substances 0.000 claims description 27
- 239000000427 antigen Substances 0.000 claims description 26
- 102000036639 antigens Human genes 0.000 claims description 26
- 108091007433 antigens Proteins 0.000 claims description 26
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 25
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 24
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- -1 cyclohexane-1-carbonyl Chemical group 0.000 claims description 8
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 210000004881 tumor cell Anatomy 0.000 claims description 6
- 206010060862 Prostate cancer Diseases 0.000 claims description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 230000006037 cell lysis Effects 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 125000006850 spacer group Chemical group 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 239000000611 antibody drug conjugate Substances 0.000 claims 43
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 43
- 108020004707 nucleic acids Proteins 0.000 claims 17
- 102000039446 nucleic acids Human genes 0.000 claims 17
- 150000007523 nucleic acids Chemical class 0.000 claims 17
- 108091026890 Coding region Proteins 0.000 claims 14
- 230000003308 immunostimulating effect Effects 0.000 claims 11
- 239000002773 nucleotide Substances 0.000 claims 11
- 125000003729 nucleotide group Chemical group 0.000 claims 11
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 10
- 239000003795 chemical substances by application Substances 0.000 claims 9
- 239000002246 antineoplastic agent Substances 0.000 claims 8
- 239000003246 corticosteroid Substances 0.000 claims 7
- 239000002955 immunomodulating agent Substances 0.000 claims 7
- 229940121354 immunomodulator Drugs 0.000 claims 7
- 230000002584 immunomodulator Effects 0.000 claims 7
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 claims 6
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 claims 6
- 229960000395 phenylpropanolamine Drugs 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 5
- 208000023958 prostate neoplasm Diseases 0.000 claims 5
- 239000003098 androgen Substances 0.000 claims 4
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 229940079322 interferon Drugs 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims 3
- 102000019034 Chemokines Human genes 0.000 claims 3
- 108010012236 Chemokines Proteins 0.000 claims 3
- 102000004127 Cytokines Human genes 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 3
- 102000000588 Interleukin-2 Human genes 0.000 claims 3
- 108010002350 Interleukin-2 Proteins 0.000 claims 3
- 108091034117 Oligonucleotide Proteins 0.000 claims 3
- 239000002671 adjuvant Substances 0.000 claims 3
- 108010044540 auristatin Proteins 0.000 claims 3
- 239000002254 cytotoxic agent Substances 0.000 claims 3
- 229940127089 cytotoxic agent Drugs 0.000 claims 3
- 231100000599 cytotoxic agent Toxicity 0.000 claims 3
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 229960004618 prednisone Drugs 0.000 claims 3
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 3
- 239000004475 Arginine Substances 0.000 claims 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical group OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 2
- 108700026244 Open Reading Frames Proteins 0.000 claims 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims 2
- 206010054094 Tumour necrosis Diseases 0.000 claims 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- 229940024606 amino acid Drugs 0.000 claims 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000025084 cell cycle arrest Effects 0.000 claims 2
- 229960002173 citrulline Drugs 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 2
- 229960003668 docetaxel Drugs 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 2
- 230000012010 growth Effects 0.000 claims 2
- 229960000890 hydrocortisone Drugs 0.000 claims 2
- 229960001438 immunostimulant agent Drugs 0.000 claims 2
- 239000003022 immunostimulating agent Substances 0.000 claims 2
- 229960003104 ornithine Drugs 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Chemical group OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 2
- 230000035755 proliferation Effects 0.000 claims 2
- 239000003381 stabilizer Substances 0.000 claims 2
- 230000004614 tumor growth Effects 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- AXKGIPZJYUNAIW-UHFFFAOYSA-N (4-aminophenyl)methanol Chemical compound NC1=CC=C(CO)C=C1 AXKGIPZJYUNAIW-UHFFFAOYSA-N 0.000 claims 1
- BQQGAGGSEMLWRS-UHFFFAOYSA-N (4-aminophenyl)methyl carbamate Chemical compound NC(=O)OCC1=CC=C(N)C=C1 BQQGAGGSEMLWRS-UHFFFAOYSA-N 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000006992 Interferon-alpha Human genes 0.000 claims 1
- 108010047761 Interferon-alpha Proteins 0.000 claims 1
- 102000008070 Interferon-gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical group OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical group CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical group CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical group CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical group C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical group CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Chemical group CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 claims 1
- 238000005481 NMR spectroscopy Methods 0.000 claims 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Chemical group OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Chemical group C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical group CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 230000022534 cell killing Effects 0.000 claims 1
- 235000013477 citrulline Nutrition 0.000 claims 1
- 238000011260 co-administration Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 210000002889 endothelial cell Anatomy 0.000 claims 1
- 239000007850 fluorescent dye Substances 0.000 claims 1
- 229940044627 gamma-interferon Drugs 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 229940127121 immunoconjugate Drugs 0.000 claims 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Chemical group CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 1
- 229960000310 isoleucine Drugs 0.000 claims 1
- 229930182817 methionine Chemical group 0.000 claims 1
- 210000004457 myocytus nodalis Anatomy 0.000 claims 1
- 201000002120 neuroendocrine carcinoma Diseases 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 claims 1
- 239000004474 valine Chemical group 0.000 claims 1
- 150000003839 salts Chemical class 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
- 229960004919 procaine Drugs 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 159000000032 aromatic acids Chemical class 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 150000002763 monocarboxylic acids Chemical class 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69239905P | 2005-06-20 | 2005-06-20 | |
| US60/692,399 | 2005-06-20 | ||
| US79236006P | 2006-04-14 | 2006-04-14 | |
| US60/792,360 | 2006-04-14 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008518359A Division JP2008546792A (ja) | 2005-06-20 | 2006-06-20 | Ｐｓｍａ抗体薬物複合体 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015095276A Division JP2015187117A (ja) | 2005-06-20 | 2015-05-07 | Ｐｓｍａ抗体薬物複合体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013100314A JP2013100314A (ja) | 2013-05-23 |
| JP2013100314A5 true JP2013100314A5 (OSRAM) | 2013-11-21 |
| JP6063747B2 JP6063747B2 (ja) | 2017-01-18 |
Family
ID=37460276
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008518359A Withdrawn JP2008546792A (ja) | 2005-06-20 | 2006-06-20 | Ｐｓｍａ抗体薬物複合体 |
| JP2013000244A Expired - Fee Related JP6063747B2 (ja) | 2005-06-20 | 2013-01-04 | Ｐｓｍａ抗体薬物複合体 |
| JP2015095276A Pending JP2015187117A (ja) | 2005-06-20 | 2015-05-07 | Ｐｓｍａ抗体薬物複合体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008518359A Withdrawn JP2008546792A (ja) | 2005-06-20 | 2006-06-20 | Ｐｓｍａ抗体薬物複合体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015095276A Pending JP2015187117A (ja) | 2005-06-20 | 2015-05-07 | Ｐｓｍａ抗体薬物複合体 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20070160617A1 (OSRAM) |
| EP (1) | EP1912677B1 (OSRAM) |
| JP (3) | JP2008546792A (OSRAM) |
| KR (3) | KR20140084242A (OSRAM) |
| CN (2) | CN103127523A (OSRAM) |
| AU (1) | AU2006262231B2 (OSRAM) |
| BR (1) | BRPI0612529A2 (OSRAM) |
| CA (1) | CA2612762C (OSRAM) |
| DK (1) | DK1912677T3 (OSRAM) |
| ES (1) | ES2440482T3 (OSRAM) |
| NZ (1) | NZ565075A (OSRAM) |
| PL (1) | PL1912677T3 (OSRAM) |
| PT (1) | PT1912677E (OSRAM) |
| WO (1) | WO2007002222A2 (OSRAM) |
Families Citing this family (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7244827B2 (en) * | 2000-04-12 | 2007-07-17 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 24P4C12 useful in treatment and detection of cancer |
| US6943235B1 (en) * | 1999-04-12 | 2005-09-13 | Agensys, Inc. | Transmembrane protein expressed in prostate cancer |
| US20050215472A1 (en) | 2001-10-23 | 2005-09-29 | Psma Development Company, Llc | PSMA formulations and uses thereof |
| EP1448588A4 (en) | 2001-10-23 | 2006-10-25 | Psma Dev Company L L C | ANTIBODIES AND MULTIMERS OF PSMA PROTEINS |
| JP4741838B2 (ja) | 2002-07-31 | 2011-08-10 | シアトル ジェネティクス，インコーポレーテッド | 癌、自己免疫疾患または感染症を治療するための薬物結合体およびその使用 |
| CN104998273A (zh) | 2003-11-06 | 2015-10-28 | 西雅图基因公司 | 能够与配体偶联的单甲基缬氨酸化合物 |
| CN101098854B (zh) | 2004-07-23 | 2012-12-05 | 恩多塞特公司 | 二价连接体及其轭合物 |
| EP1726650A1 (en) * | 2005-05-27 | 2006-11-29 | Universitätsklinikum Freiburg | Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen |
| NZ599239A (en) | 2007-03-14 | 2013-10-25 | Endocyte Inc | Binding ligand linked drug delivery conjugates of tubulysins |
| US9877965B2 (en) | 2007-06-25 | 2018-01-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
| US9138484B2 (en) | 2007-06-25 | 2015-09-22 | Endocyte, Inc. | Conjugates containing hydrophilic spacer linkers |
| RS53595B1 (sr) | 2007-07-16 | 2015-02-27 | Genentech, Inc. | Anti-cd79b antitela i imunokonjugati i metode upotrebe |
| ES2528922T3 (es) | 2007-07-16 | 2015-02-13 | Genentech, Inc. | Anticuerpos anti-CD79b humanizados e inmunoconjugados y métodos de uso |
| PL2187965T3 (pl) * | 2007-08-17 | 2020-05-18 | Purdue Research Foundation | Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania |
| US8865875B2 (en) * | 2007-08-22 | 2014-10-21 | Medarex, L.L.C. | Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions |
| US8039597B2 (en) * | 2007-09-07 | 2011-10-18 | Agensys, Inc. | Antibodies and related molecules that bind to 24P4C12 proteins |
| IL287292B (en) | 2008-01-31 | 2022-09-01 | Genentech Inc | Cycteine engineering anti-cd79b antibodies and antibody-drug conjugates |
| CA2721169A1 (en) * | 2008-04-14 | 2009-10-22 | Proscan Rx Pharma Inc. | Prostate specific membrane antigen antibodies and antigen binding fragments |
| US8852630B2 (en) | 2008-05-13 | 2014-10-07 | Yale University | Chimeric small molecules for the recruitment of antibodies to cancer cells |
| DK2291659T3 (en) | 2008-05-13 | 2015-12-21 | Univ Yale | SMALL CHEMICAL MOLECULES FOR RECRUITING ANTIBODIES TO CANCER CELLS |
| PL2326350T3 (pl) * | 2008-09-08 | 2014-03-31 | Psma Dev Company L L C | Związki do zabijania eksprymujących PSMA, opornych na taksan komórek rakowych |
| WO2010091234A2 (en) | 2009-02-06 | 2010-08-12 | The General Hospital Corporation | Methods of treating vascular lesions |
| US8309093B2 (en) * | 2009-03-06 | 2012-11-13 | Agensys, Inc. | Antibody drug conjugates (ADC) that bind to 24P4C12 proteins |
| ES2668645T3 (es) | 2010-02-08 | 2018-05-21 | Agensys, Inc. | Conjugados de fármaco y anticuerpo (ADC) que se unen a proteínas 161P2F10B |
| US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
| ES2581314T3 (es) * | 2010-03-02 | 2016-09-05 | Seattle Genetics, Inc. | Métodos de cribado de anticuerpos |
| EP2699596A4 (en) | 2011-04-22 | 2015-01-14 | Emergent Product Dev Seattle | PROSTATE-SPECIFIC MEMBRANE-BINDING PROTEINS AND COMPOSITIONS AND METHOD THEREFOR |
| SG10201605293PA (en) * | 2011-05-27 | 2016-08-30 | Ambrx Inc | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives |
| US9796754B2 (en) * | 2011-05-27 | 2017-10-24 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives |
| US20130116404A1 (en) | 2011-11-08 | 2013-05-09 | Case Western Reserve University | Targeted non-invasive imaging probes of egfr expressing cells |
| JP6684490B2 (ja) | 2012-01-09 | 2020-04-22 | ザ・スクリップス・リサーチ・インスティテュート | 超長相補性決定領域及びその使用 |
| WO2013126797A1 (en) | 2012-02-24 | 2013-08-29 | Purdue Research Foundation | Cholecystokinin b receptor targeting for imaging and therapy |
| US20140080175A1 (en) | 2012-03-29 | 2014-03-20 | Endocyte, Inc. | Processes for preparing tubulysin derivatives and conjugates thereof |
| NZ701324A (en) * | 2012-05-04 | 2016-09-30 | Pfizer | Prostate-associated antigens and vaccine-based immunotherapy regimens |
| EP3536700A1 (en) * | 2012-06-07 | 2019-09-11 | Ambrx, Inc. | Prostate-specific membrane antigen antibody drug conjugates |
| CA2876706A1 (en) * | 2012-06-14 | 2013-12-19 | Ambrx, Inc. | Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides |
| ES2680153T3 (es) | 2012-10-12 | 2018-09-04 | Adc Therapeutics Sa | Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas |
| US9662402B2 (en) | 2012-10-16 | 2017-05-30 | Endocyte, Inc. | Drug delivery conjugates containing unnatural amino acids and methods for using |
| KR102575825B1 (ko) | 2012-11-15 | 2023-09-06 | 엔도사이트, 인코포레이티드 | Psma 발현 세포에 의해 야기되는 질병을 치료하기 위한 컨쥬게이트 |
| WO2014088950A1 (en) * | 2012-12-07 | 2014-06-12 | 3M Innovative Properties Company | Method of making transparent conductors on a substrate |
| CA2902872A1 (en) | 2013-03-15 | 2014-09-18 | Regeneron Pharmaceuticals, Inc. | Biologically active molecules, conjugates thereof, and therapeutic uses |
| CN107252485A (zh) * | 2013-04-03 | 2017-10-17 | Ibc药品公司 | 用于诱导对疾病的免疫应答的组合疗法 |
| CA2913732A1 (en) | 2013-06-04 | 2014-12-11 | Cytomx Therapeutics, Inc. | Compositions and methods for conjugating activatable antibodies |
| CA2917814C (en) | 2013-07-11 | 2022-12-13 | The California Institute For Biomedical Research | Coiled coil immunoglobulin fusion proteins and compositions thereof |
| WO2015057250A1 (en) | 2013-10-18 | 2015-04-23 | Psma Development Company, Llc | Combination therapies with psma ligand conjugates |
| JP6908964B2 (ja) * | 2013-10-18 | 2021-07-28 | ピーエスエムエー ディベロップメント カンパニー，エルエルシー | Ｐｓｍａリガンドコンジュゲートによる併用療法 |
| MY194484A (en) | 2013-10-18 | 2022-11-30 | Deutsches Krebsforsch | Labeled Inhibitors of Prostate Specific Membrane Antigen (PSMA), Their use as Imaging Agents and Pharmaceutical Agents for the Treatment of Prostate Cancer |
| MX2016006219A (es) | 2013-11-14 | 2016-10-28 | Endocyte Inc | Compuestos para tomografia por emision de positrones. |
| WO2015073896A2 (en) | 2013-11-15 | 2015-05-21 | Psma Development Company, Llc | Biomarkers for psma targeted therapy for prostate cancer |
| PL3082877T3 (pl) | 2013-12-17 | 2020-02-28 | Novartis Ag | Cytotoksyczne peptydy i ich koniugaty |
| MX374342B (es) | 2014-05-22 | 2025-03-06 | Byondis Bv | Conjugacion especifica de sitio de farmacos enlazadores con anticuerpos y conjugados farmaco-anticuerpo (adc) resultantes. |
| KR20170016479A (ko) | 2014-06-13 | 2017-02-13 | 노파르티스 아게 | 아우리스타틴 유도체 및 그의 접합체 |
| EP3689910A3 (en) | 2014-09-23 | 2020-12-02 | F. Hoffmann-La Roche AG | Method of using anti-cd79b immunoconjugates |
| CA2963470A1 (en) * | 2014-10-03 | 2016-04-07 | Massachusetts Institute Of Technology | Antibodies that bind ebola glycoprotein and uses thereof |
| US10188759B2 (en) | 2015-01-07 | 2019-01-29 | Endocyte, Inc. | Conjugates for imaging |
| BR112017020149A8 (pt) | 2015-03-27 | 2023-05-02 | Regeneron Pharma | Derivados de maitansinoide, conjugados dos mesmos e métodos de uso |
| MX392478B (es) | 2015-06-22 | 2025-03-24 | Bayer Pharma AG | Conjugados de ligador-principio activo (adcs) y conjugados de ligador-profarmaco (apdcs) con grupos enzimaticamente escindibles. |
| JP2018525001A (ja) * | 2015-08-06 | 2018-09-06 | シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ | 治療用細胞内在化コンジュゲート |
| BR112018005573A2 (pt) | 2015-09-21 | 2019-01-22 | Aptevo Research And Development Llc | ?polipeptídeos de ligação a cd3? |
| WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
| EA039072B9 (ru) | 2016-01-25 | 2022-02-04 | Регенерон Фармасьютикалз, Инк. | Производные майтанзиноида, их конъюгаты и способы применения |
| KR20180123047A (ko) | 2016-03-24 | 2018-11-14 | 바이엘 파마 악티엔게젤샤프트 | 효소적으로 절단가능한 기를 갖는 세포독성 활성제의 전구약물 |
| US20170296679A1 (en) * | 2016-04-18 | 2017-10-19 | Intuitive Surgical Operations, Inc. | Compositions of Near IR Closed Chain, Sulfo-Cyanine Dyes and Prostate Specific Membrane Antigen Ligands |
| LT3464318T (lt) | 2016-06-02 | 2021-06-25 | Abbvie Inc. | Gliukokortikoidų receptorių agonistas ir jo imunokonjugatai |
| EP3471776B1 (en) | 2016-06-15 | 2022-05-04 | Bayer Pharma Aktiengesellschaft | Specific antibody-drug-conjugates with ksp inhibitors and anti-cd123-antibodies |
| US11660351B2 (en) | 2016-12-21 | 2023-05-30 | Bayer Aktiengesellschaft | Antibody drug conjugates (ADCs) having enzymatically cleavable groups |
| JP7030811B2 (ja) | 2016-12-21 | 2022-03-07 | バイエル・ファルマ・アクティエンゲゼルシャフト | Ｋｓｐ阻害剤を有する特異的抗体－薬物コンジュゲート（ａｄｃ） |
| KR20190099250A (ko) | 2016-12-21 | 2019-08-26 | 바이엘 악티엔게젤샤프트 | 효소적으로 절단가능한 기를 갖는 세포독성 활성제의 전구약물 |
| CN110418802A (zh) | 2017-01-20 | 2019-11-05 | 朱诺治疗学有限公司 | 细胞表面缀合物及相关的细胞组合物和方法 |
| WO2018178277A1 (en) | 2017-03-29 | 2018-10-04 | Avicenna Oncology Gmbh | New targeted cytotoxic isocombretaquinoline derivatives and conjugates thereof |
| AU2018250336B2 (en) | 2017-04-07 | 2025-02-20 | Juno Therapeutics, Inc. | Engineered cells expressing prostate-specific membrane antigen (PSMA) or a modified form thereof and related methods |
| PE20251254A1 (es) | 2017-05-24 | 2025-05-06 | Novartis Ag | Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer |
| EP3769786A4 (en) * | 2017-06-19 | 2021-12-08 | Sichuan Baili Pharm Co. Ltd | ANTIBODY-DRUG CONJUGATE WITH AN ACID SELF-STABILIZATION JUNCTION |
| PE20201286A1 (es) | 2017-12-01 | 2020-11-24 | Abbvie Inc | Agonista del receptor de glucocorticoides e inmunoconjugados de este |
| BR112020018948A2 (pt) * | 2018-03-23 | 2021-01-05 | Seattle Genetics, Inc. | Uso de conjugados de fármaco e anticorpo que compreendem agentes de interrupção de tubulina para tratar tumor sólido |
| WO2019183633A1 (en) | 2018-03-23 | 2019-09-26 | Case Western Reserve Univeristy | Psma targeted conjugate compounds and uses thereof |
| KR20210003135A (ko) | 2018-04-17 | 2021-01-11 | 엔도사이트, 인코포레이티드 | 암의 치료 방법 |
| KR20210042120A (ko) | 2018-08-06 | 2021-04-16 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 콘주게이트와 튜불린 저해제의 조합 |
| FR3085952B1 (fr) | 2018-09-17 | 2020-10-30 | Centre Nat Rech Scient | Conjugue anticorps-medicament comprenant des derives de quinoline |
| WO2020236808A1 (en) | 2019-05-20 | 2020-11-26 | Endocyte, Inc. | Methods for preparing psma conjugates |
| DE102019135564B4 (de) * | 2019-12-20 | 2022-05-19 | Johannes-Gutenberg-Universität Mainz | Verbindung für Smart-Drug-Delivery und pharmazeutisches Kit für duale nuklearmedizinisch-cytotoxische Theranostik |
| CN115298186B (zh) * | 2020-03-25 | 2024-09-13 | 江苏恒瑞医药股份有限公司 | 抗psma抗体-依喜替康类似物偶联物及其医药用途 |
| CA3195865A1 (en) * | 2020-10-18 | 2022-04-21 | Maria Leia Smith | Anti-cspg4 binding agents, conjugates thereof and methods of using the same |
| WO2022108992A1 (en) * | 2020-11-17 | 2022-05-27 | The Johns Hopkins University | Prostate-specific membrane antigen (psma)-targeted prodrug for selective killing of cells expressing psma |
| US20250332265A1 (en) | 2021-11-09 | 2025-10-30 | Case Western Reserve University | Psma targeted conjugate compounds and uses thereof |
| WO2024027795A1 (zh) * | 2022-08-04 | 2024-02-08 | 苏州开拓药业股份有限公司 | 包含Myc蛋白降解剂类生物活性化合物的抗体药物偶联物及其制备方法和用途 |
| CN116196428B (zh) * | 2023-04-04 | 2025-04-04 | 上海愿智生物技术有限公司 | 一种药物组合物及其应用 |
| WO2025031285A1 (zh) * | 2023-08-04 | 2025-02-13 | 江苏恒瑞医药股份有限公司 | 抗psma抗体-药物偶联物及其医药用途 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1019163A (en) * | 1963-01-23 | 1966-02-02 | Robert Dorfman | A collapsible cap or the like |
| FR2554327A1 (fr) * | 1983-11-03 | 1985-05-10 | Gamerdinger Philippe | Chapeau monopiece |
| JPS61137624U (OSRAM) * | 1985-02-15 | 1986-08-27 | ||
| JPS6270126U (OSRAM) * | 1985-10-23 | 1987-05-02 | ||
| GB8814827D0 (en) * | 1988-06-22 | 1988-07-27 | Caple I | Planar article |
| JPH0460516U (OSRAM) * | 1990-09-27 | 1992-05-25 | ||
| US6214345B1 (en) * | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| JPH0712435U (ja) * | 1993-07-29 | 1995-02-28 | 規子 山内 | 組み立て帽子セット |
| US6107090A (en) * | 1996-05-06 | 2000-08-22 | Cornell Research Foundation, Inc. | Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains |
| US5804602A (en) * | 1996-06-17 | 1998-09-08 | Guilford Pharmaceuticals Inc. | Methods of cancer treatment using naaladase inhibitors |
| US20040018194A1 (en) * | 2000-11-28 | 2004-01-29 | Francisco Joseph A. | Recombinant anti-CD30 antibodies and uses thereof |
| FR2818660B1 (fr) * | 2000-12-27 | 2005-03-11 | Agronomique Inst Nat Rech | Levures transformees par des genes augmentant leur tolerance au stress froid |
| US7256257B2 (en) * | 2001-04-30 | 2007-08-14 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| US6884869B2 (en) * | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| US20050215472A1 (en) * | 2001-10-23 | 2005-09-29 | Psma Development Company, Llc | PSMA formulations and uses thereof |
| EP1448588A4 (en) * | 2001-10-23 | 2006-10-25 | Psma Dev Company L L C | ANTIBODIES AND MULTIMERS OF PSMA PROTEINS |
| US20040161776A1 (en) * | 2001-10-23 | 2004-08-19 | Maddon Paul J. | PSMA formulations and uses thereof |
| US20040132101A1 (en) * | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| JP4741838B2 (ja) * | 2002-07-31 | 2011-08-10 | シアトル ジェネティクス，インコーポレーテッド | 癌、自己免疫疾患または感染症を治療するための薬物結合体およびその使用 |
| WO2004067564A2 (en) * | 2003-01-29 | 2004-08-12 | Protein Design Labs, Inc. | Compositions against cancer antigen liv-1 and uses thereof |
| CN104998273A (zh) * | 2003-11-06 | 2015-10-28 | 西雅图基因公司 | 能够与配体偶联的单甲基缬氨酸化合物 |
| CA2586909A1 (en) * | 2004-11-12 | 2006-12-14 | Seattle Genetics, Inc. | Auristatins having an aminobenzoic acid unit at the n terminus |
| CA2614436C (en) * | 2005-07-07 | 2016-05-17 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus |
| WO2007008848A2 (en) * | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus |
| US7750116B1 (en) * | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
-
2006
- 2006-06-20 PT PT67852830T patent/PT1912677E/pt unknown
- 2006-06-20 US US11/471,457 patent/US20070160617A1/en not_active Abandoned
- 2006-06-20 CN CN201310053174XA patent/CN103127523A/zh active Pending
- 2006-06-20 BR BRPI0612529-8A patent/BRPI0612529A2/pt not_active Application Discontinuation
- 2006-06-20 PL PL06785283T patent/PL1912677T3/pl unknown
- 2006-06-20 CA CA2612762A patent/CA2612762C/en not_active Expired - Fee Related
- 2006-06-20 AU AU2006262231A patent/AU2006262231B2/en not_active Ceased
- 2006-06-20 NZ NZ565075A patent/NZ565075A/en not_active IP Right Cessation
- 2006-06-20 KR KR1020147013703A patent/KR20140084242A/ko not_active Ceased
- 2006-06-20 KR KR1020087001546A patent/KR20080031296A/ko not_active Ceased
- 2006-06-20 CN CN2006800302414A patent/CN101287498B/zh not_active Expired - Fee Related
- 2006-06-20 JP JP2008518359A patent/JP2008546792A/ja not_active Withdrawn
- 2006-06-20 ES ES06785283.0T patent/ES2440482T3/es active Active
- 2006-06-20 DK DK06785283.0T patent/DK1912677T3/da active
- 2006-06-20 WO PCT/US2006/024182 patent/WO2007002222A2/en not_active Ceased
- 2006-06-20 KR KR1020157031397A patent/KR20150126978A/ko not_active Ceased
- 2006-06-20 EP EP06785283.0A patent/EP1912677B1/en active Active
-
2013
- 2013-01-04 JP JP2013000244A patent/JP6063747B2/ja not_active Expired - Fee Related
-
2015
- 2015-05-07 JP JP2015095276A patent/JP2015187117A/ja active Pending
-
2020
- 2020-07-06 US US16/921,811 patent/US20210023094A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013100314A5 (OSRAM) | ||
| JP2008546792A5 (OSRAM) | ||
| WO2023078273A1 (en) | Specific conjugation for an antibody-drug conjugate | |
| US12178863B2 (en) | Combination of vaccination and OX40 agonists | |
| CN101287498B (zh) | Psma抗体-药物缀合物 | |
| US9242012B2 (en) | Methods for killing PSMA-expressing, taxane-resistant cancer cells | |
| JP5632813B2 (ja) | リガンド免疫原複合体を用いる処置方法 | |
| JP2015534577A5 (OSRAM) | ||
| AU2020203191B2 (en) | Combination therapies with psma ligand conjugates | |
| US20150110814A1 (en) | Combination therapies with psma ligand conjugates | |
| JP2013518912A5 (OSRAM) | ||
| JP2013505944A5 (OSRAM) | ||
| JP2015525791A5 (OSRAM) | ||
| JP2015534578A5 (OSRAM) | ||
| EA200601761A1 (ru) | Композиции в качестве адъювантов для усиления иммунных ответов на вакцины и способы их применения | |
| JP7680375B2 (ja) | コラーゲン結合薬物担体を用いてがんを処置するための方法および組成物 | |
| JP7045047B2 (ja) | 腫瘍溶解性ウイルスの抗腫瘍効果増強剤 | |
| ES2837927T3 (es) | Terapias de combinación con conjugados de ligando de PSMA | |
| Hammerich et al. | CTLA-4 DC ECM EGFR FLT3L | |
| JP2010508248A (ja) | アテローム性動脈硬化症の治療のためのｅｄ−ｂフィブロネクチンドメインをターゲットとする融合タンパク質の使用 | |
| HK1186110A (en) | Psma antibody-drug conjugates |